BiotechTube
Laigo Bio

Laigo Bio

Leiden, Netherlands· Est.
laigobio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Laigo Bio is an early-stage biotech developing a novel targeted protein degradation platform called SureTACs (Surface Removal Targeting Chimeras). The technology uses bispecific antibodies to bring disease-causing membrane proteins into proximity with specific E3 ligases, marking them for lysosomal destruction. The company has raised €17 million in seed financing to advance its preclinical oncology and auto-immunity programs and is exploring strategic partnerships. Laigo's approach aims to tackle traditionally 'undruggable' targets with high tissue specificity.

OncologyAuto-immunity

Technology Platform

SureTACs (Surface Removal Targeting Chimeras) - a bispecific antibody platform that recruits membrane-bound E3 ubiquitin ligases to mark cell surface target proteins for lysosomal degradation.

Opportunities

Laigo's focus on degrading extracellular and membrane proteins addresses a large 'undruggable' target space neglected by intracellular-focused TPD companies, creating potential for first-in-class therapies.
The platform's inherent tissue specificity could lead to safer drugs with improved therapeutic indices.
Strong seed funding and grant support provide a solid foundation to generate compelling preclinical proof-of-concept data to attract partners or further investment.

Risk Factors

The novel SureTAC platform carries high technical risk, as the complex biology of hijacking membrane E3 ligases for lysosomal degradation is unproven clinically.
The company faces intense competition in the broader TPD field from larger, well-capitalized players.
As a preclinical-stage biotech, Laigo is dependent on raising significant additional capital to advance programs into and through clinical trials.

Competitive Landscape

Laigo competes in the targeted protein degradation space, which is dominated by companies like Arvinas, Kymera, and Nurix focused on intracellular PROTACs. Its primary differentiation is the exclusive focus on cell surface proteins. Potential competitors include companies developing lysosome-targeting chimeras (LYTACs) or antibody-based degraders, such as Orum Therapeutics or companies leveraging the Abzyme platform, but Laigo's specific use of membrane-bound E3 ligases is a unique approach.

More companies in Proteomics & Protein Engineering →More companies in Netherlands →